Ellen Engelhardt

As of April 2018 I have a dual appointment at the NKI. Four days a week I work at the PSOE in the Bleiker group where my focus is on long-term quality of life and other psychosocial outcomes of the women diagnosed with ductal carcinoma in situ (DCIS) eligible to take part in the LORD trial.

One day a week I work at C2 in the Schmidt group on the PRECISION (PREvent ductal Carcinoma In Situ Intensive Overtreatment Now) study. As of May 2020, I have also started working on a newly obtained Health Holland PPP allowance, the PREDICT-NL project. The focus of this project is to develop strategies to facilitate the embedding of good prediction/prognostic models in clinical practice.